This article is more than 5 years old. Information may no longer be current.

Paradigm Medical Industries to market Retimax diagnostic device in the US

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SALT LAKE CITY — Paradigm Medical Industries has signed an exclusive agreement with Italian ophthalmic instrument manufacturer Costruzione Strumenti Oftalmici to distribute the company's Retimax ophthalmic diagnostic device in the United States, Paradigm announced in a press release.

In addition, Paradigm will distribute additional ophthalmic products from Costruzione Strumenti Oftalmici (CSO) worldwide, the release said.

The Retimax device performs tests for the early screening and management of glaucoma, age-related maculopathy, vascular retinal degeneration and other optic nerve diseases.

"This new partnership will create many new opportunities for both organizations," Stephen Davis, president of Paradigm, said in the release. "We are excited to be chosen as CSO's exclusive distributor of their Retimax product in the domestic markets; we expect to do very well in the U.S. This new partnership will also open up new doors for future cooperative product development."